Last Monday, Kevin Tittel, our ONCOVALUE researcher, proudly presented his first poster at the ISPOR conference in Barcelona. His poster highlighted the preliminary results of our feasibility study, conducted in collaboration with clinical partners from all participating centers as part of the ONCOVALUE consortium.
This study aims to explore the current quality of our hospital data needed for health technology assessments (HTA) in early-stage breast cancer.
Kevin is thrilled to contribute with his work to ONCOVALUE’s mission of unlocking the full potential of real-world hospital data for use in health technology assessments in oncology.
